EDIT insider transaction filings
Editas Medicine, Inc. — 40 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-07. Screen EDIT transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-07 | 4 | Ellinor Patrick Thomas II — Director | Grant/award (A): 103,400 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Parison Amy — SVP, Chief Financial Officer | Sale (S): 678 @ $2.58 | EDGAR |
| 2026-07-29 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 4,928 @ $2.67 | EDGAR |
| 2026-06-22 | 4 | Connaughton Bernadette — Director | Grant/award (A): 51,700 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Scadden David — Director | Grant/award (A): 51,700 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Levy Elliott M. — Director | Grant/award (A): 51,700 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Hopfield Jessica — Director | Grant/award (A): 51,700 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Hirsch Andrew — Director | Grant/award (A): 51,700 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Parison Amy — SVP, Chief Financial Officer | Sale (S): 464 @ $2.70 | EDGAR |
| 2026-06-05 | 4 | O'Neill Gilmore Neil — CEO, Director | Sale (S): 15,380 @ $2.70 | EDGAR |
| 2026-06-05 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 731 @ $2.70 | EDGAR |
| 2026-03-16 | 4 | O'Neill Gilmore Neil — CEO, Director | Grant/award (A): 1,015,200 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Parison Amy — SVP, Chief Financial Officer | Grant/award (A): 292,856 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Grant/award (A): 292,856 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | O'Neill Gilmore Neil — CEO, Director | Sale (S): 5,394 @ $2.02 | EDGAR |
| 2026-03-04 | 4 | Parison Amy — SVP, Chief Financial Officer | Sale (S): 474 @ $2.02 | EDGAR |
| 2026-03-04 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 749 @ $2.02 | EDGAR |
| 2025-12-04 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 713 @ $2.15 | EDGAR |
| 2025-12-04 | 4 | O'Neill Gilmore Neil — CEO, Director | Sale (S): 5,603 @ $2.15 | EDGAR |
| 2025-12-04 | 4 | Parison Amy — SVP, Chief Financial Officer | Sale (S): 461 @ $2.15 | EDGAR |
| 2025-09-04 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 710 @ $2.60 | EDGAR |
| 2025-09-04 | 4 | Parison Amy — SVP, Chief Financial Officer | Sale (S): 458 @ $2.60 | EDGAR |
| 2025-09-04 | 4 | O'Neill Gilmore Neil — CEO, Director | Sale (S): 5,592 @ $2.60 | EDGAR |
| 2025-08-08 | 4 | Parison Amy — SVP, Chief Financial Officer | Sale (S): 679 @ $2.58 | EDGAR |
| 2025-08-04 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 5,121 @ $2.49 | EDGAR |
| 2025-06-10 | 4 | Scadden David — Director | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Levy Elliott M. — Director | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Connaughton Bernadette — Director | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Hopfield Jessica — Director | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Hirsch Andrew — Director | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Parison Amy — SVP, Chief Financial Officer | Sale (S): 446 @ $1.72 | EDGAR |
| 2025-06-04 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 726 @ $1.72 | EDGAR |
| 2025-06-04 | 4 | O'Neill Gilmore Neil — CEO, Director | Sale (S): 15,192 @ $1.72 | EDGAR |
| 2025-04-08 | 4 | Parison Amy — SVP, Chief Financial Officer | Grant/award (A): 34,672 (derivative) @ $0 | EDGAR |
| 2025-03-27 | 4 | Lucera Erick — EVP, CHIEF FINANCIAL OFFICER | Grant/award (A): 275,100 (derivative) @ $0 · Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-03-27 | 4 | O'Neill Gilmore Neil — CEO, Director | Grant/award (A): 828,000 (derivative) @ $0 · Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2025-03-27 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Grant/award (A): 275,100 (derivative) @ $0 · Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Lucera Erick — EVP, CHIEF FINANCIAL OFFICER | Sale (S): 4,109 @ $1.71 | EDGAR |
| 2025-03-05 | 4 | O'Neill Gilmore Neil — CEO, Director | Sale (S): 16,632 @ $1.71 | EDGAR |
| 2025-03-05 | 4 | Burkly Linda — EVP, CHIEF SCIENTIFIC OFFICER | Sale (S): 2,891 @ $1.71 | EDGAR |
Recent 8-K events — Editas Medicine, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-18 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-26 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-05-26 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-07 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-27 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=EDIT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →